Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Ther Adv Neurol Disord
.
2021 Jun 3:14:17562864211022581.
doi: 10.1177/17562864211022581.
eCollection 2021.
Authors
Hela-Felicitas Petereit
1
,
Hayrettin Tumani
2
,
Uwe K Zettl
3
Affiliations
1
Praxis Rechts vom Rhein, Köln, Germany.
2
Department of Neurology, MS Unit, University of Ulm, Oberer Eselsberg, Ulm, 89070, Germany.
3
Department of Neurology, Neuroimmunologcal Section, University of Rostock, Rostock, Germany.
PMID:
34158837
PMCID:
PMC8182197
DOI:
10.1177/17562864211022581
No abstract available
Keywords:
COVID-19; high efficacy therapy; immune response; mRNA vaccine; multiple sclerosis.